The potential of SMARCA4 and its mutually exclusive paralog SMARCA2 as therapeutic target has been already investigated in the case of lung cancer using an allosteric SMARCA4/SMARCA2 inhibitor [109]. This evidence concerns the gene SMARCA4 and lung carcinoma.